Study design
toxicity, PD, cranial irradiation
DISEASES
This is an open‐label, randomized, multicenter, phase II study. Eligible patients will be treated with durvalumab combined with up to four cycles of etoposide and platinum‐based chemotherapy (EP/EC). Patients who complete the four cycles of durvalumab plus EP/EC treatment and do not have progressive diseases (non‐PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab with anlotinib (Arm 1) or durvalumab alone (Arm 2) until confirmed PD, unacceptable toxicity or withdraw of written consent. Prophylactic cranial irradiation (PCI) is allowed at the investigators' discretion (Figure Study flow chart.